Vascular Endothelial Growth Factor Expression as a Prognostic Index in Serous Ovarian Cystoadenocarcinomas: Relationship with MIB1 Immunostaining

This publication has 19 references indexed in Scilit:

• Aberrant FGF-2, FGF-3, FGF-4 and C-ERB-B2 Gene Copy Number in Human Ovarian, Breast and Endometrial Tumours
  Growth Factors, 1996
• MIB 1 lmmunostaining in Cervical Intraepithelial Neoplasia: Prognostic Significance in Mild and Moderate Lesions
  Gynecologic and Obstetric Investigation, 1996
• Expression of Vascular Endothelial Growt Factor and Its Receptors fit and KDR in Ovarian Carcinoma
  JNCI Journal of the National Cancer Institute, 1995
• Ki67 Antigen Immunostaining (MIB 1 Monoclonal Antibody) in Serous Ovarian Tumors: Index of Proliferative Activity with Prognostic Significance
  Gynecologic Oncology, 1995
• National survey of ovarian carcinoma VI: Critical assessment of Current International Federation of Gynecology and Obstetrics Staging System
  Cancer, 1993
• Second‐line chemotherapy for recurrent carcinoma of the ovary
  Cancer, 1993
• Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
  Biochemical and Biophysical Research Communications, 1992
• Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors.
  Molecular Biology of the Cell, 1992
• Cancer statistics, 1992
  CA: A Cancer Journal for Clinicians, 1992
• Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis.
  Journal of Clinical Investigation, 1989